Clinical trial: Hypertrophic Cardiomyopathy Symptom Release by BX1514M (NCT02590809)

Eligibility criteria:
Inclusion Criteria:

          -  Patients with a typical or atypical hypertrophic cardiomyopathy (HCM) confirmed by
             imaging modalities (echo and MRI) and/or genetic tests or a relative history of HCM

          -  Left ventricular obstruction during exercise on treadmill (above 50 mmHg)

          -  Positive response to leg lifting test (obstruction reduction above 20 mmHg) at rest or
             in early recovery phase

          -  Daily symptoms as shortness of breath during exercise (NYHA2-3), non coronary chest
             pain, dizziness

          -  Correct ultrasound windows quality

          -  Sinus rhythm

          -  Optimal medical treatment

          -  For women, pregnancy test or contraception

          -  Written consent form obtained

        Exclusion Criteria:

          -  Previous treatment by BX1514M

          -  Extra-cardiac pathology with life expectancy below than 1 year

          -  No capability of consent form written

          -  Pregnancy women

          -  Secondary hypertension hypertrophy, secondary valvular disease hypertrophy

          -  Permanent atrial fibrillation

          -  Severe ventricular arrhythmia without Implantable Cardioverter Defibrillator (ICD)

          -  Severe coronary disease

          -  Severe non stabilized hypertension

          -  Severe cardiopathy (ejection fraction below 40% or demonstrated elevated end diastolic
             pressure or pulmonary pressure above 60 mmHg)

          -  Bradycardia

          -  Narrow angle glaucoma

          -  Vascular prethrombotic diseases

          -  Vascular spams

          -  Thyrotoxicosis

          -  Pheochromocytoma

          -  Severe renal failure (<30ml/mn)

          -  Patients at risk of urinary retention secondary to prostatic severe disease

          -  Raynaud's disease

          -  Non selective Monoamine Oxidase Inhibitors (MAOIs), iproniazid, nialamide or
             ephedrine, methylphenidate, phenylephrine, pseudoephedrine or digitalic

          -  Procedures modifying the peripheral venous return

          -  Participation to other research protocol
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 80 Years

Patient description (medical language): A 23-year-old man comes to the emergency department following an episode of syncope.  He was working out when he felt dizzy and passed out without head injury.  He has had 3 other episodes of light-headedness over the last year, all happening during physical activity. He never had this experience while resting. He has no other medical conditions.  The patient does not use tobacco, alcohol, or illicit drugs.  His father died suddenly at age 35.  Vital signs are within normal limits.  On physical examination, the patient has a harsh systolic murmur.  The lungs are clear with no peripheral edema. Echocardiography shows asymmetric interventricular septal hypertrophy.

Patient description (patient's own words): I'm 23, and I got admitted to the ER because I fainted all of a sudden. I was in the gym, working out, when all of a sudden, I just got dizzy and passed out. Hopefully, I didn't hit my head. It's not my first time having that kind of dizziness at the gym, never when I'm chilling at home tho. I don't have any special medical conditions and I'm not even smoking, drinking or doing drugs! My dad died suddenly when he was 35, so I'm kind of scared. My vitals were normal while at the ER and they did a physical exam and they told me my heart sounds abnormal. My lungs are ok, but I had to do an echography of my heart, and they told me it is bigger than average.

Does the patient match the trial criteria? Entailment